GTx GTXI

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Advanced Micro Devices Has 40% Upside Potential In 2014

      Headlines

      Thu, 7 Aug 2014

      NVDA ) bestselling GeForce card, the GTX 760, and is expected to offer at least similar performance with the GeForce GTX 760, while achieving in parallel lower ..... limited to the similar performance (with GTX 760) and energy hungrier R9 280X and to

    2. More on GTx Q2 results

      Headlines

      Tue, 5 Aug 2014

      GTx (NASDAQ: GTXI ) Q2 results : Revenue: $0; Operating Expenses: $10.9M (-14.8%); Operating Loss: ($10.9M) (+14.8

    3. GTx misses by $0.03

      Headlines

      Tue, 5 Aug 2014

      GTx (NASDAQ: GTXI ): Q2 EPS of -$0.15 misses by $0.03 . Press Release Post your comment!

    4. Notable earnings before Tuesday's open

      Headlines

      Mon, 4 Aug 2014

      BCRX , BLMN , CIE , CLDT , CNK , COH , CRZO , CVC , CVS , DWRE , EMR , END , ENZY , EXH , EXLP , EXPD , FE , FUN , GLDD , GTIV , GTXI , HCLP , HCP , HEP , IART , IFF , IIVI , INFI , IT , KWK , LIN , LPX , MDU , MGM , MMP , MSI , MWW , MZOR , NILE , NNN

    5. When Flexibility Meets Opportunity in the European Commercial Real Estate Market

      Headlines

      Wed, 13 Nov 2013

      We are raising GTx 's fair value on recent positive Phase II trial results for Ostarine.

    6. America: The New Europe?

      Headlines

      Wed, 2 Oct 2013

      GTx adds a European partner.

    7. GTx muscle drug fails late-stage trials, shares plunge

      Headlines

      Mon, 19 Aug 2013

      (Reuters) - GTx Inc's experimental drug to treat muscle wasting in cancer patients became its second successive lead drug to fail late-stage trials, wiping out nearly two-thirds of the market value...

    8. Dropping Coverage of GTx

      Commentary

      Sun, 24 Oct 2010

      We're dropping coverage of GTx Inc GTXI to focus our resources elsewhere.

    9. Drug Development Moves Along at GTx

      Commentary

      Fri, 17 Sep 2010

      GTx Inc. GTXI reported second-quarter results that came ..... treatment for advanced prostate cancer, GTx -758, met endpoints in a Phase II study ..... Administration, and will continue to push ahead on GTx 758. In the meantime, GTx continues to

    10. New Morningstar Analyst Report - GTx , Inc.

      Stock Reports

      Wed, 9 Jun 2010

      generate substantial revenue . Acapodene is GTx 's first in - house drug candidate . The ..... traction with urologists or oncologists . GTx may not have success in repartnering Ostarine ..... large potential patient population . If GTx can establish another partnership or independently

    « Prev1234Next »
    Content Partners